Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MRNS

Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis

Marinus Pharmaceuticals logo

About Marinus Pharmaceuticals Stock (NASDAQ:MRNS)

Advanced Chart

Key Stats

Today's Range
$0.55
$0.55
50-Day Range
$0.55
$0.55
52-Week Range
$0.22
$1.97
Volume
260 shs
Average Volume
1.88 million shs
Market Capitalization
$30.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.92
Consensus Rating
Hold

Company Overview

Marinus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

MRNS MarketRank™: 

Marinus Pharmaceuticals scored higher than 41% of companies evaluated by MarketBeat, and ranked 594th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Marinus Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Marinus Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Marinus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($1.99) to ($0.49) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Marinus Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Marinus Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Marinus Pharmaceuticals has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Marinus Pharmaceuticals' valuation and earnings.
  • Short Interest

    There is no current short interest data available for MRNS.
  • Dividend Yield

    Marinus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Marinus Pharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MRNS.
  • MarketBeat Follows

    Only 1 people have added Marinus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Marinus Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.46% of the stock of Marinus Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    98.80% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Marinus Pharmaceuticals' insider trading history.
Receive MRNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MRNS Stock News Headlines

Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
See More Headlines

MRNS Stock Analysis - Frequently Asked Questions

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) announced its earnings results on Tuesday, August, 13th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by $0.01. The biopharmaceutical company earned $8.06 million during the quarter, compared to analysts' expectations of $9.05 million. Marinus Pharmaceuticals had a negative trailing twelve-month return on equity of 7,831.35% and a negative net margin of 446.48%.
Read the conference call transcript
.

Marinus Pharmaceuticals shares reverse split on Wednesday, September 23rd 2020.The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Marinus Pharmaceuticals investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
8/13/2024
Today
7/13/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MRNS
CIK
1267813
Employees
110
Year Founded
N/A

Price Target and Rating

High Price Target
$10.00
Low Price Target
$0.50
Potential Upside/Downside
+613.3%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$141.40 million
Net Margins
-446.48%
Pretax Margin
-446.48%
Return on Equity
-7,831.35%
Return on Assets
-120.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.66
Quick Ratio
1.47

Sales & Book Value

Annual Sales
$30.99 million
Price / Sales
0.98
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.31 per share
Price / Book
1.77

Miscellaneous

Outstanding Shares
55,220,000
Free Float
52,203,000
Market Cap
$30.32 million
Optionable
Optionable
Beta
1.03

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:MRNS) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners